Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as a tablet for oral use. It is employed in the treatment of certain blood cancers, primarily in adult patients. GNH USA supplies Leukeran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leukeran (chlorambucil) is used in the treatment of hematologic malignancies.

- Chronic lymphocytic leukemia: helps achieve disease remission and prolongs survival. - Hodgkin's lymphoma: contributes to disease control as part of chemotherapy regimens. - Non‑Hodgkin lymphoma: used in combination therapy to induce remission.

Leukeran may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Loss of appetite - Fatigue or weakness - Mild leukopenia - Mild thrombocytopenia - Diarrhea

Serious or Rare Side Effects: - Severe bone marrow suppression - Secondary malignancies (e.g., acute leukemia) - Pulmonary fibrosis or interstitial lung disease - Severe allergic reactions (anaphylaxis) - Hepatic toxicity (elevated transaminases) - Renal impairment or failure

Before initiating therapy, several safety measures should be observed.

- Monitor blood counts: perform regular complete blood count tests. - Assess liver function: check hepatic enzymes periodically. - Evaluate renal function: monitor creatinine and clearance. - Avoid use in patients with known hypersensitivity to chlorambucil or similar agents. - Use caution in elderly or frail patients due to increased toxicity risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Chlorambucil can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other alkylating agents (enhanced myelosuppression). - Live vaccines (risk of infection due to immunosuppression). - Strong CYP450 inducers (e.g., phenobarbital) reducing drug exposure. - Anticoagulants (increased bleeding risk). - High‑dose radiation therapy (exacerbated tissue damage).

Moderate Interactions (Monitor Closely): - NSAIDs (potential gastrointestinal irritation). - Azole antifungals (may alter chlorambucil metabolism). - Allopurinol (possible increase in toxicity). - ACE inhibitors (monitor renal function). - Non‑live vaccines (observe for reduced efficacy).